CDK4 and breast carcinoma: With a median progression-free survival (PFS) exceeding 2 years in first-line metastatic patients, indicating long-term use, evaluating the enduring safety of CDK4/6is in breast cancer treatment is imperative (Gao et al., 2020; Harbeck et al., 2021).